{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T19:59:01Z","timestamp":1767902341925,"version":"3.49.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007543","name":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.therap.2025.02.007","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T19:29:16Z","timestamp":1741030156000},"page":"580-588","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Vaccines and the risk of Guillain-Barr\u00e9 syndrome: A French pharmacovigilance analysis"],"prefix":"10.1016","volume":"80","author":[{"given":"Marie","family":"Gligorov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9n\u00e9dicte","family":"Lebrun-Vignes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamel","family":"Masmoudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Vial","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helga","family":"Junot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Pourcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Demeret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6797-0237","authenticated-orcid":false,"given":"Kevin","family":"Bihan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2025.02.007_bib0105","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","article-title":"Guillain-Barre syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"29","author":"Sejvar","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.therap.2025.02.007_bib0110","series-title":"Fili\u00e8re de sant\u00e9 maladies rares neuromusculaires FILNEMUS. Protocole national de diagnostic et de soins (PNDS) Syndrome de Guillain-Barre","year":"2021"},{"key":"10.1016\/j.therap.2025.02.007_bib0115","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.therap.2016.02.010","article-title":"Causality assessment in pharmacovigilance: the French method and its successive updates","volume":"71","author":"Miremont-Salam\u00e9","year":"2016","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2025.02.007_bib0120","series-title":"Suivi des cas d\u2019effets ind\u00e9sirables des vaccins COVID-19. Donn\u00e9es du 25\/03\/2022-07\/04\/2022","year":"2022"},{"key":"10.1016\/j.therap.2025.02.007_bib0125","series-title":"Avis no\u00a02022. 0064\/AC\/SESPEV du 15 d\u00e9cembre 2022 du coll\u00e8ge de la Haute Autorit\u00e9 de sant\u00e9 relatif \u00e0 la vaccination des enfants de 6 mois \u00e0 4\u00a0ans \u00e0 risque de formes s\u00e9v\u00e8res de COVID-19 ou appartenant \u00e0 l\u2019entourage des personnes immunod\u00e9prim\u00e9es","year":"2022"},{"key":"10.1016\/j.therap.2025.02.007_bib0130","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/cid\/cit222","article-title":"Lack of association of Guillain-Barre syndrome with vaccinations","volume":"57","author":"Baxter","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.therap.2025.02.007_bib0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40263-019-00670-y","article-title":"Do vaccines trigger neurological diseases? Epidemiological evaluation of vaccination and neurological diseases using examples of multiple sclerosis, Guillain-Barre syndrome and narcolepsy","volume":"34","author":"Stowe","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.therap.2025.02.007_bib0140","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3389\/fpubh.2020.00361","article-title":"Do vaccines have a role as a cause of autoimmune neurological syndromes?","volume":"8","author":"Principi","year":"2020","journal-title":"Front Public Health"},{"key":"10.1016\/j.therap.2025.02.007_bib0145","first-page":"e37578","article-title":"Guillain-Barre syndrome induced by vaccination against COVID-19: a systematic review and meta-analysis","volume":"15","author":"Ogunjimi","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.therap.2025.02.007_bib0150","doi-asserted-by":"crossref","first-page":"1078197","DOI":"10.3389\/fimmu.2023.1078197","article-title":"Guillain-Barre syndrome following COVID-19 vaccines: a review of literature","volume":"14","author":"Yu","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.therap.2025.02.007_bib0155","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/s12879-022-07284-8","article-title":"Effect of gender, age and vaccine on reactogenicity and incapacity to work after COVID-19 vaccination: a survey among health care workers","volume":"22","author":"Nachtigall","year":"2022","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.therap.2025.02.007_bib0160","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1080\/14760584.2024.2315089","article-title":"Comparing reactogenicity of COVID-19 vaccine boosters: a systematic review and meta-analysis","volume":"23","author":"San Francisco Ramos","year":"2024","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.therap.2025.02.007_bib0165","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1177\/13524585221109397","article-title":"A disproportionality analysis for the association of central nervous system demyelinating diseases with COVID-19 vaccination using the World Health Organization pharmacovigilance database","volume":"28","author":"Kim","year":"2022","journal-title":"Mult Scler"},{"key":"10.1016\/j.therap.2025.02.007_bib0170","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/brain\/awaa433","article-title":"Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barre syndrome","volume":"144","author":"Keddie","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.therap.2025.02.007_bib0175","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s40261-022-01164-4","article-title":"Guillain-Barre syndrome associated with COVID-19 vaccines: a perspective from spontaneous report data","volume":"42","author":"Atzenhoffer","year":"2022","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.therap.2025.02.007_bib0180","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/jns.12507","article-title":"Associations of Guillain-Barre syndrome with coronavirus disease 2019 vaccination: disproportionality analysis using the World Health Organization pharmacovigilance database","volume":"27","author":"Kim","year":"2022","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.therap.2025.02.007_bib0185","doi-asserted-by":"crossref","first-page":"e228879","DOI":"10.1001\/jamanetworkopen.2022.8879","article-title":"Incidence of Guillain-Barre syndrome after COVID-19 vaccination in the vaccine safety datalink","volume":"5","author":"Hanson","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.therap.2025.02.007_bib0190","doi-asserted-by":"crossref","first-page":"815","DOI":"10.3390\/vaccines9080815","article-title":"Vaccinations and autoimmune diseases","volume":"9","author":"Olivieri","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.therap.2025.02.007_bib0195","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.therap.2020.02.022","article-title":"Uses of pharmacovigilance databases: an overview","volume":"75","author":"Bihan","year":"2020","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2025.02.007_bib0200","first-page":"1","article-title":"Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs","volume":"Vol. 6","author":"Weber","year":"1984"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595725000356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595725000356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T12:08:04Z","timestamp":1761912484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595725000356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0040595725000356"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2025.02.007","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccines and the risk of Guillain-Barr\u00e9 syndrome: A French pharmacovigilance analysis","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2025.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique.","name":"copyright","label":"Copyright"}]}}